TY  - EJOU
AU  - Bilen, Mehmet Asim 
AU  - Reyes, Adriana 
AU  - Bhowmick, Deb 
AU  - Maa, April 
AU  - Jr, Robert Bast, 
AU  - Pisters, Louis L. 
AU  - Lin, Sue-Hwa 
AU  - Logothetis, Christopher J. 
AU  - Tu, Shi-Ming 

TI  - Variant prostate carcinoma and elevated serum CA-125
T2  - Canadian Journal of Urology

PY  - 2014
VL  - 21
IS  - 5
SN  - 1488-5581

AB  - <b>Introduction:</b> About 10% of tumors derived from nongynecologic, noncoelomic tissues react with the OC125 antibody. Some patients with advanced prostate cancer were found to have elevated serum CA-125 level.
<br/>
<b>Materials and methods:</b> We examined the clinical history of 11 patients with castration resistant prostate cancer and an elevated serum CA-125 level. Pathological review and immunohistochemical staining were performed on tumors from eight of these patients.
<br/>
<b>Results:</b> Patients with advanced prostate cancer and an elevated serum CA-125 level responded to androgen ablative therapy (median duration, 27 months). They were predisposed to develop persistent or recurrent urinary symptoms and visceral metastases. Eight of 11 patients had a low or undetectable serum prostate-specific antigen level (≤4 ng/mL) or an elevated serum carcinoembryonic antigen level (>6 ng/mL). In 3 of 7 patients whose specimens were available for further review, the tumors contained histologic features compatible with a diagnosis of ductal or endometrioid adenocarcinoma of the prostate.
<br/>
<b>Conclusions:</b> Patients with prostate cancer and an elevated serum CA-125 level have unique clinical and pathologic characteristics. Some of these patients possess tumors compatible with a subtype of prostate cancer known as ductal adenocarcinoma. Additional studies need to be performed to elucidate the biologic basis of the various subtypes of prostate cancer.
KW  - CA-125
KW  -  ductal adenocarcinoma
KW  -  prostate cancer

DO  -